scorecardresearch
Add as a preferred source on Google
Sunday, February 22, 2026
TopicAlzheimer

Topic: Alzheimer

How semaglutide is emerging as A-Z drug, helping with diabetes, alcohol cravings & more

Health experts are now looking at whether semaglutide can also curb alcohol cravings among addicts. A look at how this GLP-1 category drug functions in humans.

There is a huge treatment gap for neurological conditions like Alzheimer’s—how to close it

Health inequities compound the problem, with people living in rural or poor communities disproportionately affected. The coverage of publicly funded medicines needs to be improved.

How a protein fragment in the brain & spinal fluid may simplify tracking Alzheimer’s progression

Researchers have identified a fragment of tau protein called MTBR-tau243. Tracking it, instead of the entire protein, may make monitoring Alzheimer's easier & less dependent on complex imaging.

Alzheimer’s can be diagnosed as early as 30—and symptoms aren’t what you’d expect

Those living with young-onset Alzheimer’s disease show more rapid – and aggressive – changes in their brain.

Alzheimer was a doctor who discovered a ‘special illness’ in his 50-year-old German patient

In ‘My Father’s Brain’, Sandeep Jauhar recounts his parent’s experience with Alzheimer’s while delving into the history – and fallout – of the disease.

‘Rare’ genetic mutation linked to Alzhiemer’s resistance in international study 

In study published in 'Nature Medicine' Monday, researchers from Colombia, Germany, & US cite case of a 67-yr-old whose cognition remained intact despite having genetic markers for Alzheimer's.

New Alzheimer’s drug Lecanemab shows promising results, but raises several questions

While lecanemab saw less decline in cognition and function of patients, the drug is effective only at a very early stage -- closer to the onset of the disease.

More accurate way to predict who will develop Alzheimer’s disease – new study

With the fast progression of research in biomarkers, we are quickly getting better at measuring and detecting early signs of Alzheimer’s.

Why US approval of Alzheimer’s drug has divided doctors over its effectiveness & uses

Despite the divide, having the drug on the market will change Alzheimer’s care, at least for some patients, and the FDA’s green light might pave the way for future therapies.

Why this woman in Colombia didn’t develop Alzheimer’s despite being at great risk for it

ScientiFix, our weekly feature, offers you a summary of the top global science stories of the week, with links to the best sources to read them.

On Camera

Youth Congress, your foolish protest helped the Modi govt climb out of the AI summit hole

In tactical terms, the shirtless protest was worse than a self-goal. Suddenly, the fiascos of the AI Summit were forgotten, and the Youth Congress’s disruption became the issue.

In the West, there’s anxiety. In India, optimism—Rishi Sunak says India poised to be leader in AI

On Wednesday, the former UK Prime Minister Rishi Sunak was speaking in New Delhi at a Carnegie & Observer Research Foundation event on AI.

MoD, IAF agree on some exemptions to HAL for Tejas Mk1A, but no compromise on ‘must-have’ capabilities

IAF is fine with accepting the aircraft with 'must-haves', even if some other steps remain pending, which may take at least another year, it is learnt.

No country is ever fully sovereign. Cold War era taught India its real meaning

India’s fraught neighbourhood places multiple constraints on its strategic choices. It leaves no time to take a deep breath, lean back and reset.